XML 190 R172.htm IDEA: XBRL DOCUMENT v3.8.0.1
Significant Contingent Liabilities and Unrecognized Commitments - Additional Information (Detail)
€ in Millions, $ in Millions, $ in Millions
1 Months Ended 12 Months Ended
Mar. 30, 1999
Aug. 31, 2012
EUR (€)
Dec. 31, 2017
TWD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
TWD ($)
Dec. 31, 2015
TWD ($)
Disclosure of contingent liabilities [line items]            
Research and development expense     $ 80,732.5 $ 2,723.8 $ 71,207.7 $ 65,544.6
Letters of Credit [member]            
Disclosure of contingent liabilities [line items]            
Amounts available under unused letters of credit | $     $ 94.9   $ 122.4  
Systems on Silicon Manufacturing Company Pte Ltd. [member]            
Disclosure of contingent liabilities [line items]            
Equity interest in joint venture 32.00%   39.00% 39.00%    
Minimum collective purchase capacity required     70.00% 70.00%    
Maximum purchase capacity required     28.00% 28.00%    
NXP B.V [member] | Systems on Silicon Manufacturing Company Pte Ltd. [member]            
Disclosure of contingent liabilities [line items]            
Equity interest in joint venture     61.00% 61.00%    
Technical Cooperation Agreement with Industrial Technology Research Institute [member]            
Disclosure of contingent liabilities [line items]            
Maximum capacity that can be used as per agreement     35.00% 35.00%    
Term of agreement     5 years 5 years    
Renewal period of agreement     Automatically renewed for successive periods of five years unless otherwise terminated by either party with one year prior notice. Automatically renewed for successive periods of five years unless otherwise terminated by either party with one year prior notice.    
Notice period for contract termination     1 year 1 year    
Customer Co-Investment Program of ASML [member]            
Disclosure of contingent liabilities [line items]            
Aggregate investment done   € 837.8        
Equity interest acquired   5.00%        
Lock-in period of investment   2 years 6 months        
Research and Development Funding Agreement with ASML [member]            
Disclosure of contingent liabilities [line items]            
Research and development expense   € 276.0